E Point Perfect
Law \ Legal

Money Laundering Watch: 2022 Year in Review


Farewell to 2022, and welcome 2023. As we do every year, let’s look back.

We highlight 12 of our most-read blog posts from 2022, which address many of the key issues we’ve examined during the past year: the Corporate Transparency Act (“CTA”) and beneficial ownership reporting; sanctions — particularly sanctions involving Russia; cryptocurrency and digital assets; BSA/AML compliance and its tension with de-risking; and implementation of the AML Act:

We now move on to 2023.  This year also will be an important and interesting year for BSA/AML and money laundering issues: criminal and civil enforcement cases continue to unfold across industries, crypto is undergoing intense scrutiny, and FinCEN must issue final regulations under the CTA and AML Act — and, possibly, as to the real estate industry. We look forward to keeping you informed throughout 2023 on these and other developments.

We also want to thank our many readers around the world who continue to make this blog such a success. The feedback we receive from financial industry professionals, compliance officers, in-house and external lawyers, BSA/AML consultants, government personnel, journalists, and others interested in this field is invaluable, and we hope you will continue to share your perspectives with us.  We pride ourselves on providing in-depth discussions of the important developments in this ever-evolving area.

If you would like to subscribe to Money Laundering Watch, please click here. To learn more about Ballard Spahr’s Anti-Money Laundering Team, please click here


Source link

Related posts

Import violations bring warnings to companies across the U.S.

Data Protection on the Blockchain: Singapore’s Personal Data Protection Commission Weighs In

California Appellate Court Holds Corporate Officer Personally Liable for Unpaid Wages

Explore Legal Immigration Options for Construction Companies

Arbitrator Should Decide Whether NY Or CA Law Should Apply

Federal Court of Appeal upholds decision invalidating claims to multiple sclerosis treatment regimen